Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the infant development, environment and Lifestyle (IDEAL) study

Therapeutic Drug Monitoring

Volumn 31, Issue 6, 2009, Pages 769-775

  Gray, Teresa R ^a   Lagasse, Linda L ^b   Smith, Lynne M ^c   Derauf, Chris ^d   Grant, Penny ^e   Shah, Rizwan ^f   Arria, Amelia M ^g   Grotta, Sheri A Della ^b   Strauss, Arthur ^h   Haning, William F ^d   Lester, Barry M ^b   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b BROWN UNIVERSITY   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e UNIVERSITY OF OKLAHOMA   (United States)

^f Blank Children's Hospital   (United States)

^g UNIVERSITY OF MARYLAND   (United States)

^h LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Amphetamines; Cannabis; Meconium; Prenatal drug exposure; Tobacco

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; CANNABINOID DERIVATIVE; CANNABIS; COCAINE; COTININE; METHAMPHETAMINE; OPIATE DERIVATIVE; TETRAHYDROCANNABINOLIC ACID;

ARTICLE; CHILD DEVELOPMENT; COMPARATIVE STUDY; DRUG DETERMINATION; DRUG USE; FEMALE; FIRST TRIMESTER PREGNANCY; GAS CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; INFANT; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MECONIUM; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SELF REPORT; THIRD TRIMESTER PREGNANCY; TOBACCO;

ADOLESCENT; ADULT; AMPHETAMINES; CANNABINOIDS; COTININE; FEMALE; HUMANS; INFANT, NEWBORN; INTERVIEWS AS TOPIC; MALE; MARIJUANA SMOKING; MATERNAL EXPOSURE; MECONIUM; NEUROTOXINS; PREGNANCY; PREGNANCY TRIMESTERS; SELF DISCLOSURE; SENSITIVITY AND SPECIFICITY; SMOKING; SUBSTANCE ABUSE DETECTION; YOUNG ADULT;

EID: 73849093276     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181bb438e     Document Type: Article

References (19)

1. Smith LM, LaGasse LL, Derauf C, et al. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics. 2006;118:1149-1156.
2. Smith LM, Lagasse LL, Derauf C, et al. Prenatal methamphetamine use and neonatal neurobehavioral outcome. Neurotoxicol Teratol. 2008;30: 20-28.
3. Gray T, Huestis M. Bioanalytical procedures for monitoring in utero drug exposure. Anal Bioanal Chem. 2007;388:1455-1465.
4. Lester BM, ElSohly M, Wright LL, et al. The maternal lifestyle study: drug use by meconium toxicology and maternal self-report. Pediatrics. 2001;107:309-317.
5. Pichini S, Puig C, Zuccaro P, et al. Assessment of exposure to opiates and cocaine during pregnancy in a Mediterranean city: preliminary results of the 'Meconium Project' Forensic Sci Int. 2005;153:59-65.
6. Arria AM, Derauf C, Lagasse LL, et al. Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study. Matern Child Health J. 2006;10:293-302.
7. Syva Company. EMIT II Plus Monoclonal Amphetamine/Methamphet-amine Assay. Newark, DE: Dade Behring; 1999.
8. Lewis DL. Forensically-acceptable determinations of gestational fetal exposure to drugs and other chemical agents. US Patent and Trademark Office 5,532,131; 1996.
9. Jacobson SW, Jacobson JL, Sokol RJ, et al. Maternal recall of alcohol, cocaine, and marijuana use during pregnancy. Neurotoxicol Teratol. 1991; 13:535-540.
10. Boumba V, Ziavrou K, Vougiouklakis T. Hair as a biological indicator of drug use, drug abuse or chronic exposure to environmental toxicants. IntJ Toxicol. 2006;25:143-163.
11. Lozano J, Garcia-Algar O, Marchei E, et al. Prevalence of gestational exposure to cannabis in a Mediterranean city by meconium analysis. Acta Paediatr. 2007;96:1734-1737.
12. Casanova OQ, Lombardero N, Behnke M, et al. Detection of cocaine exposure in the neonate. Analyses of urine, meconium, and amniotic fluid from mothers and infants exposed to cocaine. Arch Pathol Lab Med. 1994; 118:988-993.
13. Kacinko SL, Jones HE, Johnson RE, et al. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther. 2008;84:604-612.
14. Nakamura KT, Ayau EL, Uyehara CF, et al. Methamphetamine detection from meconium and amniotic fluid in guinea pigs depends on gestational age and metabolism. Dev Pharmacol Ther. 1992;19:183-190.
15. ElSohly MA, Stanford DF, Murphy TP, et al. Immunoassay and GC-MS procedures for the analysis of drugs of abuse in meconium. J Anal Toxicol. 1999;23:436-445.
16. Franssen RME, Stolk LML, van den Brand W, et al. Analysis of morphine and amphetamine in meconium with immunoassay and HPLC-diode-array detection. J Anal Toxicol. 1994;18:294-295.
17. Moore C, Lewis D, Leikin J. False-positive and false-negative rates in meconium drug testing. Clin Chem. 1995;41:1614-1616.
18. Gray TR, Kelly T, LaGasse LL, et al. Novel biomarkers of prenatal methamphetamine exposure in human meconium. Ther Drug Monit. 2008;31:70-75.
19. Gray TR, Magri R, Shakleya DM, et al. Meconium nicotine and metabolites by liquid chromatography-tandem mass spectrometry: differentiation of passive and nonexposure and correlation with neonatal outcome measures. Clin Chem. 2008;54:2018-2027.